Individuals diagnosed with chronic kidney disease (CKD) continue to increase globally. This
group of patients experience a disproportionately higher risk of cardiovascular (CV) events …

Heart failure (HF) prevalence remains high worldwide with significant sex-related and
regional differences in its presentation, management, and outcomes. In 2020, advances in …

Growing evidences have confirmed the effect of Sacubitril/Valsartan (SV) on
antihypertension and cardiac protection in general population. However, there was no …

Heart failure (HF) treatment has changed substantially over the last 30 years, leading to
significant reductions in mortality and hospital admissions in patients with HF with reduced …

Cardiorenal syndrome (CRS) is an increasingly recognized diagnostic entity associated with
high morbidity and mortality among acutely ill heart failure (HF) patients with acute and/or …

Aims Angiotensin receptor–neprilysin inhibitor (ARNI) has played an increasingly important
role in the management of heart failure (HF). However, the evidence on the benefits of ARNI …

Importance Randomized clinical trials have shown that sacubitril-valsartan reduces the risks
of mortality and hospitalization in patients with heart failure with reduced ejection fraction …

Chronic kidney disease (CKD) is a global public health problem, and cardiovascular
disease is the most common cause of death in patients with CKD. The incidence and …

Background Data regarding using angiotensin receptor-neprilysin inhibitor (ARNI) in
patients with both heart failure with reduced ejection fraction (HFrEF) and advanced chronic …

Background The data on the effects of the angiotensin receptor–neprilysin inhibitor (ARNI)
sacubitril‐valsartan (LCZ696) in chronic heart failure (CHF) patients with end‐stage renal …